Selective RIPK1 Inhibitor Compounds for Efficacy-Toxicity Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with Receptor Interacting Protein Kinase I (RIPK1) activity, such as chronic and acute inflammatory signaling, lack effective inhibitors that can modulate RIPK1-mediated pathways to address conditions like viral infections, sepsis, and neurodegenerative diseases.
Innovation Solution
Development of compounds with specific structural formulas that inhibit RIPK1 activity, including various substituents and functional groups, to target and regulate RIPK1-mediated cell death and inflammation pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RIPK1 kinase inhibitors are developed to treat inflammatory diseases, then therapeutic efficacy is improved, but drug toxicity and off-target effects worsen
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features (Formula I compounds containing particular heterocyclic rings, substituent patterns, and molecular configurations) that enable selective binding to RIPK1's ATP-binding site while avoiding off-target kinase interactions. This localized molecular design ensures the drug acts precisely on the intended target, improving therapeutic efficacy while reducing general toxicity through structural specificity rather than broad-spectrum inhibition
Solution Approach 2:
The patent employs parameter changes by systematically optimizing multiple molecular parameters including substituent types (R1-R6 groups), ring structures (W, V1-V4), and stereochemical configurations to fine-tune the inhibitor's binding affinity, selectivity, and pharmacokinetic properties. This parameter optimization allows achieving high therapeutic efficacy at low doses while minimizing toxic effects through precise molecular characterization and structure-activity relationship analysis
2Adaptability or versatility
If broad-spectrum RIPK1 inhibitors are used to cover multiple disease indications, then versatility is improved, but specificity and selective efficacy worsen
Solution Approach 1:
The patent applies universality by developing a single compound class (Formula I inhibitors) that can effectively treat multiple RIPK1-mediated diseases including viral infections, sepsis, ischemic stroke, traumatic brain injury, and neurodegenerative conditions. The core molecular scaffold maintains consistent high-affinity binding to RIPK1 across different disease contexts, allowing one inhibitor structure to address diverse pathologies through their common RIPK1-dependent mechanisms
Solution Approach 2:
The patent resolves the specificity-versatility contradiction by applying local quality through disease-specific dosing regimens, administration routes, and combination therapies tailored to each indication while maintaining the same core inhibitor molecule. For example, different dosing schedules or adjunctive treatments may be applied for viral infections versus stroke, ensuring optimal selective efficacy in each context without compromising the universal mechanism of action
3Strength
If complex molecular structures are designed to enhance RIPK1 binding affinity, then binding strength is improved, but synthesis complexity and manufacturing difficulty worsen
Solution Approach 1:
The patent applies segmentation by dividing the complex inhibitor molecule into distinct modular components (core heterocyclic ring, substituent groups R1-R6, linkers, and terminal functional groups) that can be synthesized separately and then assembled through well-established coupling reactions. This modular architecture allows complex high-affinity binders to be constructed from simpler building blocks, reducing overall synthetic complexity while maintaining strong RIPK1 binding through optimized interaction interfaces
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent parameters (不同类型的取代基, 链长, 环大小) to optimize binding affinity while monitoring and controlling synthesis difficulty. By establishing structure-activity relationships and structure-property relationships, the patent identifies molecular parameter ranges that achieve high affinity without excessive complexity, enabling practical manufacturing of potent inhibitors
Data Source
AI summary
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.